A Superior Genetic Engineering Platform
Next-Gen Adenoviral Vector Technology
Welcome To Greffex
Greffex is a genetic engineering company that has developed next generation adenoviral vector technology and a superior vaccine platform. In addition to groundbreaking gene therapy applications, Greffex can help mitigate the current pandemic and become the global vaccine platform solution to fend off future pandemics.
Greffex’s novel adenoviral vector approach integrates different strategies to overcome the limitations of earlier adenoviral systems. To minimize the induction of anti-adenoviral immune responses, Greffex vaccines are fully deleted of all endogenous adenoviral genes without the use of helper viruses (we have patented this technology).
Fully deleted adenoviral vectors better focus the immune system to a vaccine antigen, minimize interference by anti-adenoviral responses, and enable multiple repeat uses of the same construct.
- Greffex began as a genetic engineering company working on gene therapy (Hepatitis A, Cystic Fibrosis) and Transplantation therapies, before pivoting to vaccine development in 2005.
- Today, Greffex is primarily focused on vaccine commercialization although we are working with the NIH on Usher’s Syndrome and with a private company on Lysosomal Storage Diseases.
- In 2021 Greffex will have 3 vaccine candidates in clinical trials, two of which are sponsored by the NIH:
- Covid-19 vaccine (privately funded) Currently Pre-Clinical
- H5N1 vaccine (NIH contract) Currently Pre-Clinical
- Universal Flu vaccine (NIH contract) Currently in R&D
- The Covid-19 vaccine has advantages over other suppliers:
- Single Dose
- Multivalent (Spike, M & N proteins, or some combo) to provide broader protection against new strains
- Easy Distribution: No Freezer – remains stable in refrigerator
- Fully-deleted, helper-independent Ad vector based on the Ad6 which has a low prevalence in humans, thus reducing interference and increasing effectiveness of the vaccine
- Awarded patents in 2014 for the creation of a fully-deleted, helper-independent adenoviral vector platform
- Using the target disease’s genetic sequence, Greffex can create any vaccine in 3-4 weeks and produce millions of doses quickly at a fraction of the cost of traditional vaccine production
- Greffex vectors are cleaner, safe, stable, versatile, and manufactured in a standardized, cost efficient process
- NIH-sponsored animal trials demonstrated an impressive 100% survival against H5N1 (versus FDA standard of 70% in animals and 40% in humans)
- Greffex made a MERS vaccine, which is similar to Covid-19, that was highly protective in animals
Greffex presently holds 14 patents with 11 additional filings
Three vaccine candidates will be in FDA trials in 2021/2022, including a Covid-19 vaccine and H5N1 avian flu vaccine
The Greffex Platform
Greffex Receives Notice from the National Eye Institute/NIH to Begin Gene Therapy Work on Usher Syndrome Blindness
In the fall of 2020, Greffex was awarded an NIH contract to develop a gene therapy to address Usher Syndrome blindness. According to Greffex CEO, John Price, “Greffex is excited to continue its mission to provide hope to children and families who have been dealt a harsh hand. Usher Syndrome affects both hearing and vision […]
January 29, 2021 Greffex presented unofficial pre-clinical trial data this week on its H5N1 vaccine candidate that it’s been working to develop under an NIH contract. Early results are encouraging. 100% of the mice that received the Greffex H5N1 vaccine survived after being challenged with a lethal dose of H5N1. Conversely, 100% of the mice […]
January 10, 2021 Greffex, a pioneering vaccine and gene therapy company with a lab in Aurora, Colorado and headquartered in Houston, Texas began pre-clinical trials this week on its Covid-19 monovalent vaccine. This is the first step in Greffex’s Covid-19 pre-clinical trials which will subsequently involve trials for its bi-valent and tri-valent Covid-19 vaccine candidates. Greffex’s […]